Videos

Metastatic Castration-Resistant Prostate Cancer Issue 2

Metastatic Castration-Resistant Prostate Cancer Issue 2

Benjamin G. Neel, MD, faculty, Department of Medicine, Perlmutter Cancer Center, NYU School of Medicine, discusses the future of immunotherapy and how it could play a role in various tumor types.

Gynecologic Cancers

Erika P. Hamilton, MD, associate director, Breast Cancer and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses a phase 1b study examining ONT-380, an oral HER2-specific inhibitor, in combination with capecitabine and trastuzumab in the third-line setting and treatment of HER2-positive metastatic breast cancer.

James M. Kiernan, MD, professor of Urology and director of Urologic Oncology at NewYork-Presbyterian Hospital/Columbia University Medical Center in New York, discusses EXO106, a urine assay, as a promising test for high-grade prostate cancer.